AstraZeneca scrambles to address concerns about vaccine data

AstraZeneca is facing new questions today after a highly unusual reprimand from a board overseeing the company’s clinical vaccine trials.The company is scrambling to respond to allegations that it used misleading data when claiming its vaccine was 79 percent effective against COVID-19 symptoms. Nick Schifrin breaks down the latest with epidemiologist Dr. Jennifer Nuzzo of Johns Hopkins University.